Gilead tops estimates, raises full-year guidance

Gilead Sciences Inc. (NASDAQ:GILD) reported 2Q17 earnings that beat expectations and raised its 2017 full-year revenue guidance to $24-$25.5 billion from $22.5-$24.5 billion.

Total HCV revenues were $2.9 billion for the quarter, topping the $2.3 billion consensus estimate. HCV sales increased sequentially from $2.6 billion in 1Q17, although they have dwindled from $4 billion a year earlier...